Early Biological Therapy in Operated Crohn's Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience.
Crohn’s disease
biological therapy
inflammatory bowel disease
surgery
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
03 04 2023
03 04 2023
Historique:
received:
25
02
2022
medline:
5
4
2023
pubmed:
1
6
2022
entrez:
31
5
2022
Statut:
ppublish
Résumé
Two-thirds of Crohn's disease (CD) patients require surgery during their disease course. However, surgery is not curative, and endoscopic recurrence is observed in up to 90% of cases. Our aim was to investigate the impact of postoperative biological therapy on the incidence of endoscopic recurrence and long-term outcomes in CD patients. This retrospective cohort study was conducted at the Humanitas Research Hospital-IRCCS (Milan, Italy) between 2014 and 2021. All consecutive CD patients who underwent surgery and colonoscopy at 6-12 months postoperatively were eligible for inclusion. A total of 141 patients were included (42.6% female, mean age 44 years). Median follow-up was 28 months. About one-third of patients were treated with biologics at baseline colonoscopy. A higher rate of endoscopic recurrence was detected in patients without biologic therapy at the time of colonoscopy compared with those treated (80.8% vs 45.2%, P < .0001). Hospitalization and surgery occurred more in untreated patients than in subjects undergoing biological therapy (12.1% vs 0.0%, P = .01). The Kaplan-Meier curves showed that the no treatment group at baseline had a >23.3% 5-year rate of hospitalization and surgery (log-rank P = .0221) and a >49.7% 5-year rate of medical therapy escalation (log-rank P = .0013) compared with the treatment arm. In the logistic regression model, absence of biologic therapy was independently associated with the risk of endoscopic disease recurrence (odds ratio, 0.22; 95% CI, 0.1-0.51; P = .0004). Operated CD patients treated early with biologics experience decreased rates of endoscopic recurrence and improved long-term outcomes.
Sections du résumé
BACKGROUND
Two-thirds of Crohn's disease (CD) patients require surgery during their disease course. However, surgery is not curative, and endoscopic recurrence is observed in up to 90% of cases. Our aim was to investigate the impact of postoperative biological therapy on the incidence of endoscopic recurrence and long-term outcomes in CD patients.
METHODS
This retrospective cohort study was conducted at the Humanitas Research Hospital-IRCCS (Milan, Italy) between 2014 and 2021. All consecutive CD patients who underwent surgery and colonoscopy at 6-12 months postoperatively were eligible for inclusion.
RESULTS
A total of 141 patients were included (42.6% female, mean age 44 years). Median follow-up was 28 months. About one-third of patients were treated with biologics at baseline colonoscopy. A higher rate of endoscopic recurrence was detected in patients without biologic therapy at the time of colonoscopy compared with those treated (80.8% vs 45.2%, P < .0001). Hospitalization and surgery occurred more in untreated patients than in subjects undergoing biological therapy (12.1% vs 0.0%, P = .01). The Kaplan-Meier curves showed that the no treatment group at baseline had a >23.3% 5-year rate of hospitalization and surgery (log-rank P = .0221) and a >49.7% 5-year rate of medical therapy escalation (log-rank P = .0013) compared with the treatment arm. In the logistic regression model, absence of biologic therapy was independently associated with the risk of endoscopic disease recurrence (odds ratio, 0.22; 95% CI, 0.1-0.51; P = .0004).
CONCLUSION
Operated CD patients treated early with biologics experience decreased rates of endoscopic recurrence and improved long-term outcomes.
Identifiants
pubmed: 35640113
pii: 6594472
doi: 10.1093/ibd/izac110
pmc: PMC10069661
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
539-547Informations de copyright
© 2022 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Références
J Crohns Colitis. 2020 Jul 30;14(7):915-919
pubmed: 31905382
Aliment Pharmacol Ther. 2020 Oct;52(8):1353-1365
pubmed: 32876349
Gastroenterology. 2017 Jan;152(1):277-295.e3
pubmed: 27840073
Am J Gastroenterol. 2010 Feb;105(2):289-97
pubmed: 19861953
Lancet. 2015 Apr 11;385(9976):1406-17
pubmed: 25542620
Lancet Gastroenterol Hepatol. 2017 Nov;2(11):785-792
pubmed: 28838644
Gastroenterology. 2009 Feb;136(2):441-50.e1; quiz 716
pubmed: 19109962
Curr Med Res Opin. 2008 Feb;24(2):319-28
pubmed: 18067689
Aliment Pharmacol Ther. 2015 Oct;42(7):867-79
pubmed: 26314275
Gastroenterology. 2021 Apr;160(5):1570-1583
pubmed: 33359090
Lancet. 2019 Apr 27;393(10182):1699-1707
pubmed: 30929895
Clin Gastroenterol Hepatol. 2022 Mar;20(3):578-590.e4
pubmed: 33618023
Inflamm Bowel Dis. 2018 Mar 19;24(4):669-670
pubmed: 29547993
Inflamm Bowel Dis. 2018 Feb 15;24(3):490-501
pubmed: 29462395
Ann Surg. 2020 Aug;272(2):210-217
pubmed: 32675483
Inflamm Bowel Dis. 2019 Nov 14;25(12):1896-1905
pubmed: 30934053
Arq Gastroenterol. 2013 Jan-Mar;50(1):23-30
pubmed: 23657303
Gut. 2011 Dec;60(12):1754-63
pubmed: 21997558
Dig Dis Sci. 2015 Feb;60(2):299-312
pubmed: 25258034
Mayo Clin Proc. 2017 Jul;92(7):1088-1103
pubmed: 28601423
Aliment Pharmacol Ther. 2017 Jan;45(1):3-13
pubmed: 27862107
J Crohns Colitis. 2014 Feb;8(2):93-106
pubmed: 23746864
Ann Rheum Dis. 2013 Apr;72(4):517-24
pubmed: 22562972
Dig Dis. 2014;32(4):351-9
pubmed: 24969279
J Crohns Colitis. 2020 Jan 1;14(1):4-22
pubmed: 31711158
Gastroenterology. 2016 Jun;150(7):1568-1578
pubmed: 26946343
Gastroenterology. 2010 Feb;138(2):463-8; quiz e10-1
pubmed: 19818785
JAMA. 2013 May 22;309(20):2150-8
pubmed: 23695484
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Aliment Pharmacol Ther. 2012 Mar;35(6):625-33
pubmed: 22313322
Gastroenterology. 1990 Oct;99(4):956-63
pubmed: 2394349
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33
pubmed: 31294382